It has been established that an electron-deficient (η -cyclopentadienyl)rhodium(III) [Cp Rh ] complex is capable of catalyzing the decarboxylative and oxidative [2+2+2] annulation of benzoic acids with alkynes to produce substituted naphthalenes at room temperature. The appropriate choice of the additive and the solvent is crucial for this transformation. This catalyst system allowed use of oxygen as a terminal oxidant and broadened the substrate scope including both aromatic and aliphatic alkynes. In this catalysis, the electron deficient nature of the Cp Rh catalyst would cause the strong rhodium-π interaction, which accelerates the decarboxylation as well as the C-H bond cleavage.
The novel N,N,O-tridentate phenanthroline ligand (BinThro) bearing an axially chiral binaphthyl backbone prepared from BINOL was found to be an effective chiral catalyst for enantioselective addition of diethylzinc to aromatic aldehydes with high enantioselectivity (up to 95% ee).
A new synthetic route to highly fluorescent benzofuranylmethylidenebenzoxasiloles through cationic rhodium(I)/binap complex-catalyzed cascade cycloisomerization of bis(2-ethynylphenol)silanes has been developed involving 1,2-silicon and 1,3-carbon (alkyne) migrations followed by oxycyclization. The present synthesis requires only three steps, starting from commercially available dichlorodiisopropylsilane, which is markedly shorter than our previous synthesis (eight steps starting from commercially available chlorodiisopropylsilane). Theoretical calculations elucidated the mechanism of the above cascade cycloisomerization. This reaction is initiated by the formation of a rhodium vinylidene not through direct 1,2-silicon migration but rather through an unprecedented stepwise 1,5-silicon migration followed by C-Si bond-forming cyclization from a dearomatized allenylrhodium complex. Subsequent 1,3-carbon (alkyne) migration leading to a η -allenyl/propargyl-rhodium complex followed by oxycyclization through π-bond (alkyne) activation with the cationic rhodium(I) complex affords the benzofuranylmethylidenebenzoxasilole product. The structure-fluorescence property relationships of the thus obtained benzofuranylmethylidenebenzoxasiloles were investigated, which revealed that good fluorescence quantum yields were generated in the solution state (φ =69-87 %) by introduction of electron-donating alkyl and phenyl groups on two phenoxy groups. In the powder state, 4-methyl- and 4-methoxy-phenoxy derivatives exhibited efficient blue fluorescence (φ =52 % and 46 %, respectively). Especially, the 4-methylphenoxy derivative was thermally stable, and exhibited strong narrow-band fluorescence in the film state (blue, φ =95 %) and redshifted strong narrow-band fluorescence (green, φ =90 %) in the crystalline state as a result of the formation of an offset π-stacked dimer; the latter was confirmed by X-ray crystallographic analysis and by theoretical calculations.
Rhodium-catalyzed enantioselective desymmetrizing intramolecular hydrosilylation of symmetrically disubstituted hydrosilanes is described. The original axially chiral phenanthroline ligand (S)-BinThro (Binol-derived phenanthroline) was found to work as an effective chiral catalyst for this transformation. A chiral silicon stereogenic center is one of the chiral motifs gaining much attention in asymmetric syntheses and the present protocol provides cyclic five-membered organosilanes incorporating chiral silicon centers with high enantioselectivities (up to 91 % ee). The putative active Rh(I) catalyst takes the form of an N,N,O-tridentate coordination complex, as determined by several complementary experiments.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.